SCHEMBL24423908

SCHEMBL24423908

COC(=O)C1CCN(C(=O)c2cc[nH]n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
ALDH1A1 P00352 6/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 2/20 0.48
GLA P06280 1/20 0.48
PKM P14618 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
HTT P42858 2/20 0.46
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24423441 0.77 KDM5A (0.59) TSHRALDH1A1GAAKDM4EGLA
SCHEMBL10724061 0.77 TSHR (0.78) TSHRALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL13139384 0.77 RECQL (0.47) TSHRALDH1A1GAASMN1; SMN2L3MBTL1
SCHEMBL3308470 0.77 GNE (0.49) TSHRALDH1A1SMN1; SMN2L3MBTL1NPC1
SCHEMBL14731435 0.74 PARP1 (0.44)
SCHEMBL28478520 0.74 L3MBTL1 (0.39) ALDH1A1GAASMN1; SMN2L3MBTL1NPC1
SCHEMBL3117292 0.74 SIGMAR1 (0.50) HPGD
SCHEMBL2835506 0.74 TSHR (0.68) TSHRALDH1A1GAASMN1; SMN2NPC1
SCHEMBL20029119 0.73 SMN1; SMN2 (0.53) TSHRALDH1A1SMN1; SMN2CYP1A2NPC1
SCHEMBL25090742 0.73 TSHR (0.47) TSHRALDH1A1GAAKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD TSHR 391/4885ALDH1A1 542/4885GAA 2221/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD TSHR 142/4885ALDH1A1 1374/4885GAA 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.